{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:07:46Z","timestamp":1793315266465,"version":"4.5.0"},"reference-count":242,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023J011357"],"award-info":[{"award-number":["2023J011357"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong","doi-asserted-by":"publisher","award":["202112060725"],"award-info":[{"award-number":["202112060725"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong","doi-asserted-by":"publisher","award":["202412050668"],"award-info":[{"award-number":["202412050668"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong","doi-asserted-by":"publisher","award":["202412060875"],"award-info":[{"award-number":["202412060875"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015642","name":"Project of Shandong Province Higher Educational Science and Technology Program","doi-asserted-by":"publisher","award":["SDYWZGKCJHLH202467"],"award-info":[{"award-number":["SDYWZGKCJHLH202467"]}],"id":[{"id":"10.13039\/501100015642","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biopha.2025.118164","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:38:33Z","timestamp":1750394313000},"page":"118164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Mechanisms and therapeutic potential of pharmacological agents targeting inflammasomes"],"prefix":"10.1016","volume":"189","author":[{"given":"Haitao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duomeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixin","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baihai","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41392-021-00650-z","article-title":"Inflammasomes as therapeutic targets in human diseases","volume":"6","author":"Li","year":"2021","journal-title":"Signal transduction and targeted therapy"},{"key":"10.1016\/j.biopha.2025.118164_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41421-020-0167-x","article-title":"Inflammasome activation and regulation: toward a better understanding of complex mechanisms","volume":"6","author":"Zheng","year":"2020","journal-title":"Cell discovery"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41392-023-01687-y","article-title":"The role of inflammasomes in human diseases and their potential as therapeutic targets","volume":"9","author":"Yao","year":"2024","journal-title":"Signal transduction and targeted therapy"},{"issue":"6","key":"10.1016\/j.biopha.2025.118164_bib4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","article-title":"Interaction between microbiota and immunity in health and disease","volume":"30","author":"Zheng","year":"2020","journal-title":"Cell research"},{"issue":"8","key":"10.1016\/j.biopha.2025.118164_bib5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nature reviews Immunology"},{"issue":"7944","key":"10.1016\/j.biopha.2025.118164_bib6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41586-022-05570-8","article-title":"Cryo-EM structures of the active NLRP3 inflammasome disc","volume":"613","author":"Xiao","year":"2023","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.biopha.2025.118164_bib7","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.it.2022.10.003","article-title":"The NLRP3 inflammasome: regulation by metabolic signals","volume":"43","author":"Olona","year":"2022","journal-title":"Trends in immunology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib8","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41467-024-44990-0","article-title":"Pathogenic NLRP3 mutants form constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1beta production","volume":"15","author":"Molina-Lopez","year":"2024","journal-title":"Nature communications"},{"key":"10.1016\/j.biopha.2025.118164_bib9","doi-asserted-by":"crossref","first-page":"1006654","DOI":"10.3389\/fimmu.2022.1006654","article-title":"The NLRP3 inflammasome as a new target in respiratory disorders treatment","volume":"13","author":"Leszczynska","year":"2022","journal-title":"Frontiers in immunology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41573-023-00822-2","article-title":"Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets","volume":"23","author":"Vande Walle","year":"2024","journal-title":"Nature reviews Drug discovery"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.molmed.2023.10.001","article-title":"Therapeutic potential of PANoptosis: innate sensors, inflammasomes, and RIPKs in PANoptosomes","volume":"30","author":"Pandeya","year":"2024","journal-title":"Trends in molecular medicine"},{"issue":"5","key":"10.1016\/j.biopha.2025.118164_bib12","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nsmb.3199","article-title":"Molecular basis of caspase-1 polymerization and its inhibition by a new capping mechanism","volume":"23","author":"Lu","year":"2016","journal-title":"Nature structural & molecular biology"},{"issue":"5","key":"10.1016\/j.biopha.2025.118164_bib13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1074-7613(00)80209-5","article-title":"Caspase-1 activation of IL-1beta and IL-18 are essential for Shigella flexneri-induced inflammation","volume":"12","author":"Sansonetti","year":"2000","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.biopha.2025.118164_bib14","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.immuni.2024.04.015","article-title":"Structural transitions enable interleukin-18 maturation and signaling","volume":"57","author":"Dong","year":"2024","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.biopha.2025.118164_bib15","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2020.02.002","article-title":"Structural Mechanism for GSDMD Targeting by Autoprocessed Caspases in Pyroptosis","volume":"180","author":"Wang","year":"2020","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.biopha.2025.118164_bib16","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/cr.2015.124","article-title":"Gasdermin D: the long-awaited executioner of pyroptosis","volume":"25","author":"Man","year":"2015","journal-title":"Cell research"},{"issue":"8","key":"10.1016\/j.biopha.2025.118164_bib17","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.immuni.2022.06.007","article-title":"Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling","volume":"55","author":"Xian","year":"2022","journal-title":"Immunity"},{"issue":"7717","key":"10.1016\/j.biopha.2025.118164_bib18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41586-018-0372-z","article-title":"New mitochondrial DNA synthesis enables NLRP3 inflammasome activation","volume":"560","author":"Zhong","year":"2018","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.biopha.2025.118164_bib19","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s41422-018-0112-9","article-title":"Author Correction: Mitochondrial DNA synthesis fuels NLRP3 inflammasome","volume":"28","author":"Coll","year":"2018","journal-title":"Cell research"},{"key":"10.1016\/j.biopha.2025.118164_bib20","doi-asserted-by":"crossref","first-page":"13727","DOI":"10.1038\/ncomms13727","article-title":"The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3","volume":"7","author":"Song","year":"2016","journal-title":"Nature communications"},{"key":"10.1016\/j.biopha.2025.118164_bib21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbi.2024.02.001","article-title":"Role of pyroptosis in the pathogenesis of various neurological diseases","volume":"117","author":"Oladapo","year":"2024","journal-title":"Brain, behavior, and immunity"},{"issue":"3","key":"10.1016\/j.biopha.2025.118164_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.immuni.2012.01.009","article-title":"Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis","volume":"36","author":"Shimada","year":"2012","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.biopha.2025.118164_bib23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/bjd\/ljad421","article-title":"Role of the NLRP1 inflammasome in skin cancer and inflammatory skin diseases","volume":"190","author":"Calabrese","year":"2024","journal-title":"The British journal of dermatology"},{"issue":"11","key":"10.1016\/j.biopha.2025.118164_bib24","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41577-021-00588-x","article-title":"Inflammasome activation at the crux of severe COVID-19","volume":"21","author":"Vora","year":"2021","journal-title":"Nature reviews Immunology"},{"issue":"6","key":"10.1016\/j.biopha.2025.118164_bib25","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"The Lancet Rheumatology"},{"issue":"3","key":"10.1016\/j.biopha.2025.118164_bib26","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s15010-022-01904-w","article-title":"DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function","volume":"51","author":"Madurka","year":"2023","journal-title":"Infection"},{"issue":"7761","key":"10.1016\/j.biopha.2025.118164_bib27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41586-019-1295-z","article-title":"Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome","volume":"570","author":"Sharif","year":"2019","journal-title":"Nature"},{"issue":"7237","key":"10.1016\/j.biopha.2025.118164_bib28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature07725","article-title":"AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC","volume":"458","author":"Hornung","year":"2009","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.biopha.2025.118164_bib29","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1016\/j.cell.2021.11.011","article-title":"NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation","volume":"184","author":"Andreeva","year":"2021","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biopha.2025.118164_bib30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.immuni.2012.02.014","article-title":"Structures of the HIN domain:DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor","volume":"36","author":"Jin","year":"2012","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.biopha.2025.118164_bib31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/ni.1864","article-title":"The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses","volume":"11","author":"Rathinam","year":"2010","journal-title":"Nature immunology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib32","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.1038\/s41467-023-43691-4","article-title":"Assembly mechanism of the inflammasome sensor AIM2 revealed by single molecule analysis","volume":"14","author":"Sharma","year":"2023","journal-title":"Nature communications"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/MCB.00857-13","article-title":"Role of the HIN domain in regulation of innate immune responses","volume":"34","author":"Shaw","year":"2014","journal-title":"Molecular and cellular biology"},{"key":"10.1016\/j.biopha.2025.118164_bib34","doi-asserted-by":"crossref","first-page":"15489","DOI":"10.1038\/srep15489","article-title":"Defective mitochondrial fission augments NLRP3 inflammasome activation","volume":"5","author":"Park","year":"2015","journal-title":"Scientific reports"},{"issue":"11","key":"10.1016\/j.biopha.2025.118164_bib35","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41423-022-00922-w","article-title":"How location and cellular signaling combine to activate the NLRP3 inflammasome","volume":"19","author":"Akbal","year":"2022","journal-title":"Cellular & molecular immunology"},{"key":"10.1016\/j.biopha.2025.118164_bib36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3892\/ijmm.2022.5130","article-title":"Focus on the role of mitochondria in NLRP3 inflammasome activation: A prospective target for the treatment of ischemic stroke (Review)","volume":"49","author":"Zhang","year":"2022","journal-title":"International journal of molecular medicine"},{"issue":"2","key":"10.1016\/j.biopha.2025.118164_bib37","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.gendis.2023.01.009","article-title":"Fantastic voyage: The journey of NLRP3 inflammasome activation","volume":"11","author":"Que","year":"2024","journal-title":"Genes & diseases"},{"key":"10.1016\/j.biopha.2025.118164_bib38","doi-asserted-by":"crossref","first-page":"3462530","DOI":"10.1155\/2019\/3462530","article-title":"ER Stress Activates the NLRP3 Inflammasome: A Novel Mechanism of Atherosclerosis","volume":"2019","author":"Chen","year":"2019","journal-title":"Oxidative medicine and cellular longevity"},{"issue":"12","key":"10.1016\/j.biopha.2025.118164_bib39","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202006194","article-title":"The NLRP3-inflammasome as a sensor of organelle dysfunction","volume":"219","author":"Seoane","year":"2020","journal-title":"The Journal of cell biology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib40","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41467-017-02682-y","article-title":"Human caspase-4 detects tetra-acylated LPS and cytosolic Francisella and functions differently from murine caspase-11","volume":"9","author":"Lagrange","year":"2018","journal-title":"Nature communications"},{"key":"10.1016\/j.biopha.2025.118164_bib41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coi.2015.01.007","article-title":"Non-canonical activation of inflammatory caspases by cytosolic LPS in innate immunity","volume":"32","author":"Yang","year":"2015","journal-title":"Current opinion in immunology"},{"key":"10.1016\/j.biopha.2025.118164_bib42","first-page":"131","article-title":"Novel perspectives on non-canonical inflammasome activation","volume":"4","author":"Diamond","year":"2015","journal-title":"ImmunoTargets and therapy"},{"issue":"4","key":"10.1016\/j.biopha.2025.118164_bib43","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.immuni.2023.03.003","article-title":"The orphan receptor Nur77 binds cytoplasmic LPS to activate the non-canonical NLRP3 inflammasome","volume":"56","author":"Zhu","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib44","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41467-019-09482-6","article-title":"The lncRNA Neat1 promotes activation of inflammasomes in macrophages","volume":"10","author":"Zhang","year":"2019","journal-title":"Nature communications"},{"issue":"5","key":"10.1016\/j.biopha.2025.118164_bib45","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41590-021-00886-5","article-title":"NLRP3 inflammasome in cancer and metabolic diseases","volume":"22","author":"Sharma","year":"2021","journal-title":"Nature immunology"},{"issue":"3","key":"10.1016\/j.biopha.2025.118164_bib46","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cmet.2020.07.016","article-title":"The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation","volume":"32","author":"Hooftman","year":"2020","journal-title":"Cell metabolism"},{"issue":"8","key":"10.1016\/j.biopha.2025.118164_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114516","article-title":"Fatty acid synthesis promotes inflammasome activation through NLRP3 palmitoylation","volume":"43","author":"Leishman","year":"2024","journal-title":"Cell reports"},{"key":"10.1016\/j.biopha.2025.118164_bib48","doi-asserted-by":"crossref","first-page":"1232629","DOI":"10.3389\/fimmu.2023.1232629","article-title":"Reframing the link between metabolism and NLRP3 inflammasome: therapeutic opportunities","volume":"14","author":"Ortega","year":"2023","journal-title":"Frontiers in immunology"},{"issue":"11","key":"10.1016\/j.biopha.2025.118164_bib49","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.cell.2023.04.025","article-title":"A 360 degrees view of the inflammasome: Mechanisms of activation, cell death, and diseases","volume":"186","author":"Barnett","year":"2023","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.biopha.2025.118164_bib50","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.chembiol.2024.04.006","article-title":"Metabolism-inflammasome crosstalk shapes innate and adaptive immunity","volume":"31","author":"Wu","year":"2024","journal-title":"Cell chemical biology"},{"issue":"6","key":"10.1016\/j.biopha.2025.118164_bib51","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1083\/jcb.201602089","article-title":"The cell biology of inflammasomes: Mechanisms of inflammasome activation and regulation","volume":"213","author":"Sharma","year":"2016","journal-title":"The Journal of cell biology"},{"issue":"2","key":"10.1016\/j.biopha.2025.118164_bib52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrmicro2070","article-title":"Pyroptosis: host cell death and inflammation","volume":"7","author":"Bergsbaken","year":"2009","journal-title":"Nature reviews Microbiology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.coi.2009.01.006","article-title":"Sensing pathogens and danger signals by the inflammasome","volume":"21","author":"Pedra","year":"2009","journal-title":"Current opinion in immunology"},{"key":"10.1016\/j.biopha.2025.118164_bib54","doi-asserted-by":"crossref","first-page":"1364911","DOI":"10.3389\/fimmu.2024.1364911","article-title":"Pyroptosis: a new insight into intestinal inflammation and cancer","volume":"15","author":"Chao","year":"2024","journal-title":"Frontiers in immunology"},{"key":"10.1016\/j.biopha.2025.118164_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.919973","article-title":"Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment","volume":"13","author":"Ihim","year":"2022","journal-title":"Frontiers in immunology"},{"issue":"4","key":"10.1016\/j.biopha.2025.118164_bib56","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","article-title":"Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity","volume":"50","author":"Mantovani","year":"2019","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.biopha.2025.118164_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113581","article-title":"The tetrapeptide sequence of IL-18 and IL-1beta regulates their recruitment and activation by inflammatory caspases","volume":"42","author":"Exconde","year":"2023","journal-title":"Cell reports"},{"key":"10.1016\/j.biopha.2025.118164_bib58","article-title":"Role of the NLRP3 inflammasome in autoimmune diseases","volume":"130","author":"Li","year":"2020","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"issue":"7849","key":"10.1016\/j.biopha.2025.118164_bib59","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41586-021-03231-w","article-title":"AIM2 in regulatory T cells restrains autoimmune diseases","volume":"591","author":"Chou","year":"2021","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2025.118164_bib60","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41577-021-00572-5","article-title":"Phase separation in immune signalling","volume":"22","author":"Xiao","year":"2022","journal-title":"Nature reviews Immunology"},{"issue":"6","key":"10.1016\/j.biopha.2025.118164_bib61","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.it.2024.04.009","article-title":"Liquid-liquid phase separation in innate immunity","volume":"45","author":"Liu","year":"2024","journal-title":"Trends in immunology"},{"issue":"23","key":"10.1016\/j.biopha.2025.118164_bib62","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1016\/j.cell.2021.09.032","article-title":"Phase separation drives RNA virus-induced activation of the NLRP6 inflammasome","volume":"184","author":"Shen","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2025.118164_bib63","doi-asserted-by":"crossref","first-page":"1086192","DOI":"10.3389\/fimmu.2023.1086192","article-title":"Phase separation in innate immune response and inflammation-related diseases","volume":"14","author":"Ma","year":"2023","journal-title":"Frontiers in immunology"},{"issue":"2","key":"10.1016\/j.biopha.2025.118164_bib64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41422-021-00594-7","article-title":"It's just a phase: NLRP6 phase separations drive signaling","volume":"32","author":"Tweedell","year":"2022","journal-title":"Cell research"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib65","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-020-0145-7","article-title":"NLRP3 inflammasome as a novel therapeutic target for Alzheimer's disease","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal transduction and targeted therapy"},{"issue":"3","key":"10.1016\/j.biopha.2025.118164_bib66","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/19490976.2019.1592421","article-title":"Gut bacteria signaling to mitochondria in intestinal inflammation and cancer","volume":"11","author":"Jackson","year":"2020","journal-title":"Gut microbes"},{"key":"10.1016\/j.biopha.2025.118164_bib67","first-page":"3076","article-title":"Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome","volume":"107","author":"Miao","year":"2010"},{"issue":"7366","key":"10.1016\/j.biopha.2025.118164_bib68","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature10510","article-title":"The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus","volume":"477","author":"Zhao","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118164_bib69","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coi.2018.06.005","article-title":"An update on the NLRP3 inflammasome and influenza: the road to redemption or perdition?","volume":"54","author":"Tate","year":"2018","journal-title":"Current opinion in immunology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib70","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s10020-020-00172-4","article-title":"Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?","volume":"26","author":"Andersson","year":"2020","journal-title":"Molecular medicine"},{"issue":"7914","key":"10.1016\/j.biopha.2025.118164_bib71","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-022-04802-1","article-title":"Inflammasome activation in infected macrophages drives COVID-19 pathology","volume":"606","author":"Sefik","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2025.118164_bib72","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5582\/bst.2020.01029","article-title":"NEK7: a potential therapy target for NLRP3-related diseases","volume":"14","author":"Liu","year":"2020","journal-title":"Bioscience trends"},{"issue":"7734","key":"10.1016\/j.biopha.2025.118164_bib73","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41586-018-0761-3","article-title":"PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation","volume":"564","author":"Chen","year":"2018","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.biopha.2025.118164_bib74","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","article-title":"Mechanism and Regulation of NLRP3 Inflammasome Activation","volume":"41","author":"He","year":"2016","journal-title":"Trends in biochemical sciences"},{"issue":"7590","key":"10.1016\/j.biopha.2025.118164_bib75","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nature16959","article-title":"NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux","volume":"530","author":"He","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118164_bib76","article-title":"Inhibition of NLRP3 inflammasome activation by A20 through modulation of NEK7","volume":"121","author":"Yu","year":"2024"},{"issue":"2","key":"10.1016\/j.biopha.2025.118164_bib77","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41577-018-0111-6","article-title":"Trans-Golgi network breaks away to activate NLRP3","volume":"19","author":"Bordon","year":"2019","journal-title":"Nature reviews Immunology"},{"issue":"3","key":"10.1016\/j.biopha.2025.118164_bib78","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/imm.13628","article-title":"Inactivation of mitochondrial pyruvate carrier promotes NLRP3 inflammasome activation and gout development via metabolic reprogramming","volume":"169","author":"Chen","year":"2023","journal-title":"Immunology"},{"issue":"7329","key":"10.1016\/j.biopha.2025.118164_bib79","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature09663","article-title":"A role for mitochondria in NLRP3 inflammasome activation","volume":"469","author":"Zhou","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2025.118164_bib80","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019102201","article-title":"PLK4 deubiquitination by Spata2-CYLD suppresses NEK7-mediated NLRP3 inflammasome activation at the centrosome","volume":"39","author":"Yang","year":"2020","journal-title":"The EMBO journal"},{"issue":"10","key":"10.1016\/j.biopha.2025.118164_bib81","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/abbs\/gmw080","article-title":"NEK7: a novel promising therapy target for NLRP3-related inflammatory diseases","volume":"48","author":"Xu","year":"2016","journal-title":"Acta biochimica et biophysica Sinica"},{"key":"10.1016\/j.biopha.2025.118164_bib82","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annual review of immunology"},{"issue":"9","key":"10.1016\/j.biopha.2025.118164_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000354","article-title":"MCC950\/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition","volume":"17","author":"Vande Walle","year":"2019","journal-title":"PLoS biology"},{"issue":"23","key":"10.1016\/j.biopha.2025.118164_bib84","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1002\/j.1460-2075.1994.tb06897.x","article-title":"Identification of Src, Fyn, Lyn, PI3K and Abl SH3 domain ligands using phage display libraries","volume":"13","author":"Rickles","year":"1994","journal-title":"The EMBO journal"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib85","doi-asserted-by":"crossref","first-page":"17920","DOI":"10.1038\/s41598-020-74786-3","article-title":"Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1beta and islet cellular death","volume":"10","author":"Matsuoka","year":"2020","journal-title":"Scientific reports"},{"issue":"8","key":"10.1016\/j.biopha.2025.118164_bib86","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1161\/ATVBAHA.117.309575","article-title":"NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report","volume":"37","author":"van der Heijden","year":"2017","journal-title":"Arteriosclerosis, thrombosis, and vascular biology"},{"issue":"3","key":"10.1016\/j.biopha.2025.118164_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23030522","article-title":"Inhibiting the NLRP3 Inflammasome Activation with MCC950 Ameliorates Diabetic Encephalopathy in db\/db Mice","volume":"23","author":"Zhai","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2025.118164_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154748","article-title":"Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy","volume":"118","author":"Wu","year":"2021","journal-title":"Metabolism: clinical and experimental"},{"key":"10.1016\/j.biopha.2025.118164_bib89","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbi.2023.11.031","article-title":"MCC950 reduces autophagy and improves cognitive function by inhibiting NLRP3-dependent neuroinflammation in a rat model of Alzheimer's disease","volume":"116","author":"Naeem","year":"2024","journal-title":"Brain, behavior, and immunity"},{"key":"10.1016\/j.biopha.2025.118164_bib90","doi-asserted-by":"crossref","first-page":"4525988","DOI":"10.1155\/2021\/4525988","article-title":"VX765, a Specific Caspase-1 Inhibitor, Alleviates Lung Ischemia Reperfusion Injury by Suppressing Endothelial Pyroptosis and Barrier Dysfunction","volume":"2021","author":"Wu","year":"2021","journal-title":"BioMed research international"},{"issue":"5","key":"10.1016\/j.biopha.2025.118164_bib91","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41419-022-04966-8","article-title":"Novel role for caspase 1 inhibitor VX765 in suppressing NLRP3 inflammasome assembly and atherosclerosis via promoting mitophagy and efferocytosis","volume":"13","author":"Jin","year":"2022","journal-title":"Cell death & disease"},{"key":"10.1016\/j.biopha.2025.118164_bib92","first-page":"12","article-title":"The anti-caspase 1 inhibitor VX-765 reduces immune activation, CD4(+) T cell depletion, viral load, and total HIV-1 DNA in HIV-1 infected humanized mice","author":"Amand","year":"2023","journal-title":"eLife"},{"issue":"2","key":"10.1016\/j.biopha.2025.118164_bib93","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s13311-011-0039-z","article-title":"Interleukin-1beta biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice","volume":"8","author":"Maroso","year":"2011","journal-title":"Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics"},{"issue":"12","key":"10.1016\/j.biopha.2025.118164_bib94","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1007\/s12031-022-02088-6","article-title":"VX-765 Alleviates beta-Amyloid Deposition and Secondary Degeneration in the Ipsilateral Hippocampus and Ameliorates Cognitive Decline after Focal Cortical Infarction in Rats","volume":"72","author":"Dong","year":"2022","journal-title":"Journal of molecular neuroscience: MN"},{"issue":"9","key":"10.1016\/j.biopha.2025.118164_bib95","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.4103\/1673-5374.306096","article-title":"VX-765 reduces neuroinflammation after spinal cord injury in mice","volume":"16","author":"Chen","year":"2021","journal-title":"Neural regeneration research"},{"issue":"2","key":"10.1016\/j.biopha.2025.118164_bib96","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.bbrc.2019.03.202","article-title":"Caspase-1 inhibition mediates neuroprotection in experimental stroke by polarizing M2 microglia\/macrophage and suppressing NF-kappaB activation","volume":"513","author":"Li","year":"2019","journal-title":"Biochemical and biophysical research communications"},{"key":"10.1016\/j.biopha.2025.118164_bib97","first-page":"9593","article-title":"Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy","volume":"113","author":"Bassil","year":"2016"},{"issue":"10","key":"10.1016\/j.biopha.2025.118164_bib98","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.bcp.2013.03.008","article-title":"A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome","volume":"85","author":"Liu","year":"2013","journal-title":"Biochemical pharmacology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib99","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12272-021-01307-9","article-title":"Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases","volume":"44","author":"Seok","year":"2021","journal-title":"Archives of pharmacal research"},{"issue":"6","key":"10.1016\/j.biopha.2025.118164_bib100","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201810248","article-title":"Inflammasomes in neuroinflammatory and neurodegenerative diseases","volume":"11","author":"Voet","year":"2019","journal-title":"EMBO molecular medicine"},{"issue":"16","key":"10.1016\/j.biopha.2025.118164_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26164996","article-title":"Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models","volume":"26","author":"Das","year":"2021","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.biopha.2025.118164_bib102","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2023.5238","article-title":"Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review)","volume":"51","author":"Zhang","year":"2023","journal-title":"International journal of molecular medicine"},{"key":"10.1016\/j.biopha.2025.118164_bib103","article-title":"Piperlongumine Is an NLRP3 Inhibitor With Anti-inflammatory Activity","volume":"12","author":"Shi","year":"2021","journal-title":"Frontiers in pharmacology"},{"issue":"4","key":"10.1016\/j.biopha.2025.118164_bib104","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/FJC.0000000000000070","article-title":"Molecule 16673-34-0: a new tool in our arsenal against inflammation","volume":"63","author":"Lipinski","year":"2014","journal-title":"Journal of cardiovascular pharmacology"},{"issue":"4","key":"10.1016\/j.biopha.2025.118164_bib105","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/FJC.0000000000000053","article-title":"A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse","volume":"63","author":"Marchetti","year":"2014","journal-title":"Journal of cardiovascular pharmacology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib106","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/FJC.0000000000000931","article-title":"Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure","volume":"77","author":"Wohlford","year":"2020","journal-title":"Journal of cardiovascular pharmacology"},{"issue":"5","key":"10.1016\/j.biopha.2025.118164_bib107","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kluck","year":"2020","journal-title":"The Lancet Rheumatology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib108","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13075-018-1664-2","article-title":"NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis","volume":"20","author":"Marchetti","year":"2018","journal-title":"Arthritis research & therapy"},{"issue":"7","key":"10.1016\/j.biopha.2025.118164_bib109","first-page":"E1530","article-title":"OLT1177, a beta-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/j.biopha.2025.118164_bib112","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nature medicine"},{"issue":"7434","key":"10.1016\/j.biopha.2025.118164_bib113","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature11729","article-title":"NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP\/PS1 mice","volume":"493","author":"Heneka","year":"2013","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.biopha.2025.118164_bib114","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41583-018-0055-7","article-title":"Inflammasome signalling in brain function and neurodegenerative disease","volume":"19","author":"Heneka","year":"2018","journal-title":"Nature reviews Neuroscience"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10753-022-01730-0","article-title":"Role of NLRP3 Inflammasome and Its Inhibitors as Emerging Therapeutic Drug Candidate for Alzheimer's Disease: a Review of Mechanism of Activation, Regulation, and Inhibition","volume":"46","author":"Sharma","year":"2023","journal-title":"Inflammation"},{"key":"10.1016\/j.biopha.2025.118164_bib116","unstructured":"Inflazome\u2019s Somalix Demonstrates Positive Safety, Tolerability and Pharmacodynamic Profile in its Phase I Study."},{"issue":"3","key":"10.1016\/j.biopha.2025.118164_bib117","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrd.2017.226","article-title":"Drug development in the era of precision medicine","volume":"17","author":"Dugger","year":"2018","journal-title":"Nature reviews Drug discovery"},{"issue":"8","key":"10.1016\/j.biopha.2025.118164_bib119","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nature reviews Drug discovery"},{"issue":"8","key":"10.1016\/j.biopha.2025.118164_bib120","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nature reviews Drug discovery"},{"issue":"6","key":"10.1016\/j.biopha.2025.118164_bib121","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1586\/eci.10.66","article-title":"Canakinumab: a human anti-IL-1beta monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes","volume":"6","author":"Church","year":"2010","journal-title":"Expert review of clinical immunology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib122","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/mabs.2.1.10328","article-title":"Canakinumab","volume":"2","author":"Dhimolea","year":"2010","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib123","doi-asserted-by":"crossref","first-page":"14846","DOI":"10.1038\/s41598-021-94298-y","article-title":"Selective activation of pro-anti-IL-1beta antibody enhances specificity for autoinflammatory disorder therapy","volume":"11","author":"Lin","year":"2021","journal-title":"Scientific reports"},{"issue":"23","key":"10.1016\/j.biopha.2025.118164_bib124","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.biopha.2025.118164_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2015.12.003","article-title":"Preclinical characterization and clinical development of ILARIS((R)) (canakinumab) for the treatment of autoinflammatory diseases","volume":"32","author":"Gram","year":"2016","journal-title":"Current opinion in chemical biology"},{"issue":"12","key":"10.1016\/j.biopha.2025.118164_bib126","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"The New England journal of medicine"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib127","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/20009666.2018.1428023","article-title":"Canakinumab and cardiovascular outcomes: results of the CANTOS trial","volume":"8","author":"Shah","year":"2018","journal-title":"Journal of community hospital internal medicine perspectives"},{"issue":"10118","key":"10.1016\/j.biopha.2025.118164_bib128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118164_bib129","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2474-12-153","article-title":"Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study","volume":"12","author":"Alten","year":"2011","journal-title":"BMC musculoskeletal disorders"},{"key":"10.1016\/j.biopha.2025.118164_bib130","doi-asserted-by":"crossref","first-page":"7840724","DOI":"10.1155\/2016\/7840724","article-title":"The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review","volume":"2016","author":"Baskar","year":"2016","journal-title":"Cardiology research and practice"},{"key":"10.1016\/j.biopha.2025.118164_bib131","series-title":"Bethesda (MD)","article-title":"Drugs and Lactation Database (LactMed(R))","author":"Anakinra","year":"2006"},{"issue":"6","key":"10.1016\/j.biopha.2025.118164_bib132","first-page":"319","article-title":"The modulating influence of enkephalins on the bone marrow haemopoiesis in stress","volume":"36","author":"Goldberg","year":"1990","journal-title":"Folia biologica"},{"issue":"6","key":"10.1016\/j.biopha.2025.118164_bib133","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"10.1016\/j.biopha.2025.118164_bib134","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra Therapy for Non-cancer Inflammatory Diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Frontiers in pharmacology"},{"issue":"9","key":"10.1016\/j.biopha.2025.118164_bib135","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc09-0533","article-title":"Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes","volume":"32","author":"Larsen","year":"2009","journal-title":"Diabetes care"},{"issue":"15","key":"10.1016\/j.biopha.2025.118164_bib136","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa065213","article-title":"Interleukin-1-receptor antagonist in type 2 diabetes mellitus","volume":"356","author":"Larsen","year":"2007","journal-title":"The New England journal of medicine"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib137","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13075-019-1843-9","article-title":"Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease","volume":"21","author":"Cavalli","year":"2019","journal-title":"Arthritis research & therapy"},{"key":"10.1016\/j.biopha.2025.118164_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109075","article-title":"Current evidence on the use of anakinra in COVID-19","volume":"111","author":"Khani","year":"2022","journal-title":"International immunopharmacology"},{"issue":"34","key":"10.1016\/j.biopha.2025.118164_bib139","doi-asserted-by":"crossref","first-page":"21096","DOI":"10.1074\/jbc.272.34.21096","article-title":"Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo","volume":"272","author":"Pierce","year":"1997","journal-title":"The Journal of biological chemistry"},{"issue":"6","key":"10.1016\/j.biopha.2025.118164_bib140","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.4049\/jimmunol.0902199","article-title":"A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs","volume":"184","author":"Denny","year":"2010","journal-title":"Journal of immunology"},{"issue":"3","key":"10.1016\/j.biopha.2025.118164_bib141","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1042\/BJ20121651","article-title":"The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system","volume":"451","author":"Strickson","year":"2013","journal-title":"The Biochemical journal"},{"key":"10.1016\/j.biopha.2025.118164_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106033","article-title":"Pathway network of pyroptosis and its potential inhibitors in acute kidney injury","volume":"175","author":"Li","year":"2022","journal-title":"Pharmacological research"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib143","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1021\/acsinfecdis.1c00522","article-title":"Exploration of BAY 11-7082 as a Potential Antibiotic","volume":"8","author":"Coles","year":"2022","journal-title":"ACS infectious diseases"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib144","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1186\/s12967-024-05384-4","article-title":"IkappaBalpha kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers","volume":"22","author":"Guruvaiah","year":"2024","journal-title":"Journal of translational medicine"},{"issue":"Pt 1","key":"10.1016\/j.biopha.2025.118164_bib145","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbrc.2022.05.090","article-title":"BAY 11-7082 inhibits the secretion of interleukin-6 by senescent human microglia","volume":"617","author":"Cook","year":"2022","journal-title":"Biochemical and biophysical research communications"},{"issue":"11","key":"10.1016\/j.biopha.2025.118164_bib146","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3748\/wjg.v28.i11.1139","article-title":"Quercetin exerts anti-inflammatory effects via inhibiting tumor necrosis factor-alpha-induced matrix metalloproteinase-9 expression in normal human gastric epithelial cells","volume":"28","author":"Hsieh","year":"2022","journal-title":"World journal of gastroenterology"},{"key":"10.1016\/j.biopha.2025.118164_bib147","unstructured":"Glyburide. In: Drugs and Lactation Database (LactMed(R)). Bethesda (MD); 2006."},{"issue":"10","key":"10.1016\/j.biopha.2025.118164_bib148","doi-asserted-by":"crossref","first-page":"6590","DOI":"10.1007\/s12035-022-02998-x","article-title":"Glibenclamide Directly Prevents Neuroinflammation by Targeting SUR1-TRPM4-Mediated NLRP3 Inflammasome Activation In Microglia","volume":"59","author":"He","year":"2022","journal-title":"Molecular neurobiology"},{"issue":"5876","key":"10.1016\/j.biopha.2025.118164_bib149","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1126\/science.1156995","article-title":"Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica","volume":"320","author":"Dostert","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.118164_bib150","first-page":"7606","article-title":"Reactive cysteine persulfides and S-polythiolation regulate oxidative stress and redox signaling","volume":"111","author":"Ida","year":"2014"},{"issue":"5","key":"10.1016\/j.biopha.2025.118164_bib151","doi-asserted-by":"crossref","first-page":"9183","DOI":"10.3390\/molecules20059183","article-title":"Curcumin, inflammation, and chronic diseases: how are they linked?","volume":"20","author":"He","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2025.118164_bib152","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fphar.2016.00369","article-title":"Curcumin Represses NLRP3 Inflammasome Activation via TLR4\/MyD88\/NF-kappaB and P2X7R Signaling in PMA-Induced Macrophages","volume":"7","author":"Kong","year":"2016","journal-title":"Frontiers in pharmacology"},{"issue":"10","key":"10.1016\/j.biopha.2025.118164_bib153","doi-asserted-by":"crossref","DOI":"10.3390\/foods6100092","article-title":"Curcumin: A Review of Its Effects on Human Health","volume":"6","author":"Hewlings","year":"2017","journal-title":"Foods"},{"key":"10.1016\/j.biopha.2025.118164_bib154","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.12659\/MSM.908714","article-title":"Curcumin Attenuates Pulmonary Inflammation in Lipopolysaccharide Induced Acute Lung Injury in Neonatal Rat Model by Activating Peroxisome Proliferator-Activated Receptor gamma (PPARgamma) Pathway","volume":"24","author":"Cheng","year":"2018","journal-title":"Medical science monitor: international medical journal of experimental and clinical research"},{"key":"10.1016\/j.biopha.2025.118164_bib155","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/803971","article-title":"An Organ System Approach to Explore the Antioxidative, Anti-Inflammatory, and Cytoprotective Actions of Resveratrol","volume":"2015","author":"Malhotra","year":"2015","journal-title":"Oxidative medicine and cellular longevity"},{"issue":"3","key":"10.1016\/j.biopha.2025.118164_bib156","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/gerona\/glu029","article-title":"Resveratrol encapsulated in novel fusogenic liposomes activates Nrf2 and attenuates oxidative stress in cerebromicrovascular endothelial cells from aged rats","volume":"70","author":"Csiszar","year":"2015","journal-title":"The journals of gerontology Series A, Biological sciences and medical sciences"},{"issue":"2","key":"10.1016\/j.biopha.2025.118164_bib157","doi-asserted-by":"crossref","first-page":"634","DOI":"10.2337\/db10-0386","article-title":"Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK\/SIRT1-independent pathway","volume":"60","author":"Kitada","year":"2011","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib158","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1038\/s41598-017-08055-1","article-title":"Beta-hydroxybutyrate, an endogenic NLRP3 inflammasome inhibitor, attenuates stress-induced behavioral and inflammatory responses","volume":"7","author":"Yamanashi","year":"2017","journal-title":"Scientific reports"},{"key":"10.1016\/j.biopha.2025.118164_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2023.148567","article-title":"Infusions of beta-hydroxybutyrate, an endogenous NLRP3 inflammasome inhibitor, produce antidepressant-like effects on learned helplessness rats through BDNF-TrkB signaling and AMPA receptor activation, and strengthen learning ability","volume":"1821","author":"Shirayama","year":"2023","journal-title":"Brain research"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib160","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-020-01948-5","article-title":"beta-Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer's disease pathology","volume":"17","author":"Shippy","year":"2020","journal-title":"Journal of neuroinflammation"},{"key":"10.1016\/j.biopha.2025.118164_bib161","article-title":"3,4-Methylenedioxy-beta-Nitrostyrene Alleviates Dextran Sulfate Sodium-Induced Mouse Colitis by Inhibiting the NLRP3 Inflammasome","volume":"13","author":"Zheng","year":"2022","journal-title":"Frontiers in pharmacology"},{"issue":"11-12","key":"10.1016\/j.biopha.2025.118164_bib162","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1080\/08941939.2022.2128117","article-title":"Targeting the PANoptosome with 3,4-Methylenedioxy-beta-Nitrostyrene, Reduces PANoptosis and Protects the Kidney against Renal Ischemia-Reperfusion Injury","volume":"35","author":"Uysal","year":"2022","journal-title":"Journal of investigative surgery: the official journal of the Academy of Surgical Research"},{"key":"10.1016\/j.biopha.2025.118164_bib163","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3389\/fonc.2020.01378","article-title":"Immune Cells Combined With NLRP3 Inflammasome Inhibitor Exert Better Antitumor Effect on Pancreatic Ductal Adenocarcinoma","volume":"10","author":"Liu","year":"2020","journal-title":"Frontiers in oncology"},{"issue":"2","key":"10.1016\/j.biopha.2025.118164_bib164","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1074\/jbc.M113.515080","article-title":"3,4-methylenedioxy-beta-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome","volume":"289","author":"He","year":"2014","journal-title":"The Journal of biological chemistry"},{"issue":"9","key":"10.1016\/j.biopha.2025.118164_bib165","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jacbts.2023.03.017","article-title":"Inflammasome Signaling, Thromboinflammation, and Venous Thromboembolism","volume":"8","author":"Potere","year":"2023","journal-title":"JACC Basic to translational science"},{"key":"10.1016\/j.biopha.2025.118164_bib166","doi-asserted-by":"crossref","first-page":"1109938","DOI":"10.3389\/fimmu.2022.1109938","article-title":"The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors","volume":"13","author":"Zhan","year":"2022","journal-title":"Frontiers in immunology"},{"issue":"4","key":"10.1016\/j.biopha.2025.118164_bib167","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.7150\/ijbs.85851","article-title":"Dioscin Alleviates Periodontitis by Inhibiting NLRP3 Inflammasome Activation via Regulation of K(+) Homeostasis and Mitochondrial Function","volume":"20","author":"Jiang","year":"2024","journal-title":"International journal of biological sciences"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib168","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201905977","article-title":"A New NLRP3 Inflammasome Inhibitor, Dioscin, Promotes Osteogenesis","volume":"16","author":"Yin","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.biopha.2025.118164_bib169","doi-asserted-by":"crossref","first-page":"1051612","DOI":"10.3389\/fcell.2022.1051612","article-title":"The role of NLRP3 inflammasome in digestive system malignancy","volume":"10","author":"Sun","year":"2022","journal-title":"Frontiers in cell and developmental biology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib170","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1038\/s41467-018-06522-5","article-title":"Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases","volume":"9","author":"Xu","year":"2018","journal-title":"Nature communications"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib171","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci14010096","article-title":"Epigallocatechin-3-Gallate and Genistein for Decreasing Gut Dysbiosis, Inhibiting Inflammasomes, and Aiding Autophagy in Alzheimer's Disease","volume":"14","author":"Muraleedharan","year":"2024","journal-title":"Brain sciences"},{"issue":"11","key":"10.1016\/j.biopha.2025.118164_bib172","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24112138","article-title":"Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis","volume":"24","author":"Lee","year":"2019","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.biopha.2025.118164_bib173","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0302818","article-title":"Vitamin D regulates COVID-19 associated severity by suppressing the NLRP3 inflammasome pathway","volume":"19","author":"Khalil","year":"2024","journal-title":"PloS one"},{"key":"10.1016\/j.biopha.2025.118164_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111596","article-title":"Vitamin D protects against high glucose-induced pancreatic beta-cell dysfunction via AMPK-NLRP3 inflammasome pathway","volume":"547","author":"Wu","year":"2022","journal-title":"Molecular and cellular endocrinology"},{"key":"10.1016\/j.biopha.2025.118164_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jri.2021.103286","article-title":"Progesterone and vitamin D downregulate the activation of the NLRP1\/NLRP3 inflammasomes and TLR4-MyD88-NF-kappaB pathway in monocytes from pregnant women with preeclampsia","volume":"144","author":"Matias","year":"2021","journal-title":"Journal of reproductive immunology"},{"key":"10.1016\/j.biopha.2025.118164_bib176","article-title":"Sulforaphane decreases oxidative stress and inhibits NLRP3 inflammasome activation in a mouse model of ulcerative colitis","volume":"175","author":"Zhou","year":"2024","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.biopha.2025.118164_bib177","article-title":"Inflammasome and Its Therapeutic Targeting in Rheumatoid Arthritis","volume":"12","author":"Jiang","year":"2021","journal-title":"Frontiers in immunology"},{"key":"10.1016\/j.biopha.2025.118164_bib178","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.931690","article-title":"Role of NLRP3 Inflammasome in Rheumatoid Arthritis","volume":"13","author":"Yin","year":"2022","journal-title":"Frontiers in immunology"},{"issue":"7","key":"10.1016\/j.biopha.2025.118164_bib179","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/08916934.2022.2103802","article-title":"AIM2-inflammasome role in systemic lupus erythematous and rheumatoid arthritis","volume":"55","author":"Uresti-Rivera","year":"2022","journal-title":"Autoimmunity"},{"key":"10.1016\/j.biopha.2025.118164_bib180","doi-asserted-by":"crossref","first-page":"1693730","DOI":"10.1155\/2020\/1693730","article-title":"Expression of AIM2 in Rheumatoid Arthritis and Its Role on Fibroblast-Like Synoviocytes","volume":"2020","author":"Chen","year":"2020","journal-title":"Mediators of inflammation"},{"issue":"3","key":"10.1016\/j.biopha.2025.118164_bib181","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s10753-023-01795-5","article-title":"Therapeutic Potential of Targeting the NLRP3 Inflammasome in Rheumatoid Arthritis","volume":"46","author":"Gao","year":"2023","journal-title":"Inflammation"},{"issue":"4","key":"10.1016\/j.biopha.2025.118164_bib182","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/mi.2017.19","article-title":"Inflammasomes and intestinal inflammation","volume":"10","author":"Zmora","year":"2017","journal-title":"Mucosal immunology"},{"issue":"9","key":"10.1016\/j.biopha.2025.118164_bib183","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1111\/bph.15773","article-title":"Rhein regulates redox-mediated activation of NLRP3 inflammasomes in intestinal inflammation through macrophage-activated crosstalk","volume":"179","author":"Zhou","year":"2022","journal-title":"British journal of pharmacology"},{"issue":"11","key":"10.1016\/j.biopha.2025.118164_bib184","doi-asserted-by":"crossref","DOI":"10.1111\/cmi.13079","article-title":"Canonical and noncanonical inflammasomes in intestinal epithelial cells","volume":"21","author":"Winsor","year":"2019","journal-title":"Cellular microbiology"},{"key":"10.1016\/j.biopha.2025.118164_bib185","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.919567","article-title":"Caspase-4 and -5 Biology in the Pathogenesis of Inflammatory Bowel Disease","volume":"13","author":"Smith","year":"2022","journal-title":"Frontiers in pharmacology"},{"issue":"3","key":"10.1016\/j.biopha.2025.118164_bib186","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41385-019-0247-0","article-title":"Intestinal epithelial NAIP\/NLRC4 restricts systemic dissemination of the adapted pathogen Salmonella Typhimurium due to site-specific bacterial PAMP expression","volume":"13","author":"Hausmann","year":"2020","journal-title":"Mucosal immunology"},{"key":"10.1016\/j.biopha.2025.118164_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2020.100863","article-title":"The NAIP\/NLRC4 inflammasome in infection and pathology","volume":"76","author":"Bauer","year":"2020","journal-title":"Molecular aspects of medicine"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib188","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.12153","article-title":"NLRP3 inflammasome in sepsis (Review)","volume":"24","author":"Shi","year":"2021","journal-title":"Molecular medicine reports"},{"key":"10.1016\/j.biopha.2025.118164_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154574","article-title":"Matrine suppresses NLRP3 inflammasome activation via regulating PTPN2\/JNK\/SREBP2 pathway in sepsis","volume":"109","author":"Wang","year":"2023","journal-title":"Phytomedicine: international journal of phytotherapy and phytopharmacology"},{"issue":"6","key":"10.1016\/j.biopha.2025.118164_bib190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234039","article-title":"NLRP3 inflammasome inhibition attenuates sepsis-induced platelet activation and prevents multi-organ injury in cecal-ligation puncture","volume":"15","author":"Cornelius","year":"2020","journal-title":"PloS one"},{"issue":"3","key":"10.1016\/j.biopha.2025.118164_bib191","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3892\/etm.2023.12117","article-title":"MCC950 improves lipopolysaccharide\u2011induced systemic inflammation in mice by relieving pyroptosis in blood neutrophils","volume":"26","author":"Miao","year":"2023","journal-title":"Experimental and therapeutic medicine"},{"issue":"6","key":"10.1016\/j.biopha.2025.118164_bib192","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1164\/rccm.201604-0892OC","article-title":"NLRP3 Inflammasome Deficiency Protects against Microbial Sepsis via Increased Lipoxin B(4) Synthesis","volume":"196","author":"Lee","year":"2017","journal-title":"American journal of respiratory and critical care medicine"},{"issue":"4","key":"10.1016\/j.biopha.2025.118164_bib193","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20182091","article-title":"Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia","volume":"217","author":"Tang","year":"2020","journal-title":"The Journal of experimental medicine"},{"key":"10.1016\/j.biopha.2025.118164_bib194","doi-asserted-by":"crossref","first-page":"1125246","DOI":"10.3389\/fimmu.2023.1125246","article-title":"The development of COVID-19 treatment","volume":"14","author":"Yuan","year":"2023","journal-title":"Frontiers in immunology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib195","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s12864-024-10246-w","article-title":"Comprehensive genomic analysis of the SARS-CoV-2 Omicron variant BA.2.76 in Jining City, China, 2022","volume":"25","author":"Yin","year":"2024","journal-title":"BMC Genomics"},{"issue":"2","key":"10.1016\/j.biopha.2025.118164_bib196","doi-asserted-by":"crossref","DOI":"10.3390\/v16020213","article-title":"Investigating the Nexus of NLRP3 Inflammasomes and COVID-19 Pathogenesis: Unraveling Molecular Triggers and Therapeutic Strategies","volume":"16","author":"He","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2025.118164_bib197","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.cytogfr.2021.06.002","article-title":"The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies","volume":"61","author":"Zhao","year":"2021","journal-title":"Cytokine & growth factor reviews"},{"issue":"7","key":"10.1016\/j.biopha.2025.118164_bib198","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.14336\/AD.2021.0318","article-title":"Targeting NLRP3 Inflammasome in the Treatment Of Diabetes and Diabetic Complications: Role of Natural Compounds from Herbal Medicine","volume":"12","author":"Bai","year":"2021","journal-title":"Aging and disease"},{"issue":"2","key":"10.1016\/j.biopha.2025.118164_bib199","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.2279","article-title":"The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance","volume":"17","author":"Vandanmagsar","year":"2011","journal-title":"Nature medicine"},{"issue":"5","key":"10.1016\/j.biopha.2025.118164_bib200","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/ni.2022","article-title":"Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling","volume":"12","author":"Wen","year":"2011","journal-title":"Nature immunology"},{"key":"10.1016\/j.biopha.2025.118164_bib201","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fimmu.2013.00050","article-title":"Mechanisms of disease: inflammasome activation and the development of type 2 diabetes","volume":"4","author":"Grant","year":"2013","journal-title":"Frontiers in immunology"},{"key":"10.1016\/j.biopha.2025.118164_bib202","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.clim.2017.10.003","article-title":"Gain-of-function variants in NLRP1 protect against the development of diabetic kidney disease: NLRP1 inflammasome role in metabolic stress sensing?","volume":"187","author":"Soares","year":"2018","journal-title":"Clinical immunology"},{"issue":"8","key":"10.1016\/j.biopha.2025.118164_bib203","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084537","article-title":"NLRP3 Inflammasome in Acute and Chronic Liver Diseases","volume":"25","author":"Sayaf","year":"2024","journal-title":"International journal of molecular sciences"},{"issue":"8","key":"10.1016\/j.biopha.2025.118164_bib204","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/bph.14938","article-title":"Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3\/NF-kappaB pathway in mice","volume":"177","author":"Wang","year":"2020","journal-title":"British journal of pharmacology"},{"key":"10.1016\/j.biopha.2025.118164_bib205","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-pathmechdis-032521-102529","article-title":"Role of the Inflammasome in Liver Disease","volume":"17","author":"de Carvalho Ribeiro","year":"2022","journal-title":"Annual review of pathology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib206","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/apt.15030","article-title":"Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3\/7 activation in subjects with non-alcoholic fatty liver disease","volume":"49","author":"Shiffman","year":"2019","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"10.1016\/j.biopha.2025.118164_bib207","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172715","article-title":"Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy","volume":"864","author":"Yu","year":"2019","journal-title":"European journal of pharmacology"},{"issue":"7","key":"10.1016\/j.biopha.2025.118164_bib208","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrgastro.2015.94","article-title":"Inflammasome activation and function in liver disease","volume":"12","author":"Szabo","year":"2015","journal-title":"Nature reviews Gastroenterology & hepatology"},{"key":"10.1016\/j.biopha.2025.118164_bib209","article-title":"The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment","volume":"13","author":"Yu","year":"2022","journal-title":"Frontiers in pharmacology"},{"issue":"18","key":"10.1016\/j.biopha.2025.118164_bib210","first-page":"8158","article-title":"Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation","volume":"23","author":"Liu","year":"2019","journal-title":"European review for medical and pharmacological sciences"},{"issue":"4","key":"10.1016\/j.biopha.2025.118164_bib211","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s13105-022-00909-1","article-title":"Pyroptosis in inflammation-related respiratory disease","volume":"78","author":"Feng","year":"2022","journal-title":"Journal of physiology and biochemistry"},{"key":"10.1016\/j.biopha.2025.118164_bib212","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2024.5349","article-title":"NLRP3 inflammasome mediates abnormal epithelial regeneration and distal lung remodeling in silica\u2011induced lung fibrosis","volume":"53","author":"Zhou","year":"2024","journal-title":"International journal of molecular medicine"},{"issue":"8","key":"10.1016\/j.biopha.2025.118164_bib213","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acsmedchemlett.3c00311","article-title":"Pyridazine Derivatives as NLRP3 Inhibitors for Treating Asthma, COPD, Parkinson's Disease, and Alzheimer's Disease","volume":"14","author":"Sabnis","year":"2023","journal-title":"ACS medicinal chemistry letters"},{"key":"10.1016\/j.biopha.2025.118164_bib214","doi-asserted-by":"crossref","DOI":"10.1007\/s12026-024-09497-2","article-title":"Assessment of NLRP3 inflammasome activation in patients with chronic obstructive pulmonary disease before and after lung transplantation","author":"Rumora","year":"2024","journal-title":"Immunologic research"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib215","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ajpath.2013.09.007","article-title":"New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease","volume":"184","author":"De Nardo","year":"2014","journal-title":"The American journal of pathology"},{"issue":"2","key":"10.1016\/j.biopha.2025.118164_bib216","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bpa.12478","article-title":"Inflammasomes as therapeutic targets for Alzheimer's disease","volume":"27","author":"White","year":"2017","journal-title":"Brain pathology"},{"key":"10.1016\/j.biopha.2025.118164_bib217","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.701282","article-title":"Activation of NLRP3 Inflammasome and Onset of Alzheimer's Disease","volume":"12","author":"Bai","year":"2021","journal-title":"Frontiers in immunology"},{"issue":"8","key":"10.1016\/j.biopha.2025.118164_bib218","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ni.1636","article-title":"The NALP3 inflammasome is involved in the innate immune response to amyloid-beta","volume":"9","author":"Halle","year":"2008","journal-title":"Nature immunology"},{"key":"10.1016\/j.biopha.2025.118164_bib219","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109941","article-title":"NLRP3 inflammasome signalling in Alzheimer's disease","volume":"252","author":"McManus","year":"2024","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.biopha.2025.118164_bib220","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1007\/s11064-020-03121-z","article-title":"Mechanisms of NLRP3 Inflammasome Activation: Its Role in the Treatment of Alzheimer's Disease","volume":"45","author":"Zhang","year":"2020","journal-title":"Neurochemical research"},{"issue":"4","key":"10.1016\/j.biopha.2025.118164_bib221","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3233\/JAD-230567","article-title":"NLRP3 Inflammasome: An Emerging Therapeutic Target for Alzheimer's Disease","volume":"96","author":"Tao","year":"2023","journal-title":"Journal of Alzheimer's disease: JAD"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib222","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055375","article-title":"Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies","volume":"8","author":"Codolo","year":"2013","journal-title":"PloS one"},{"issue":"465","key":"10.1016\/j.biopha.2025.118164_bib223","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah4066","article-title":"Inflammasome inhibition prevents alpha-synuclein pathology and dopaminergic neurodegeneration in mice","volume":"10","author":"Gordon","year":"2018","journal-title":"Science translational medicine"},{"key":"10.1016\/j.biopha.2025.118164_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2020.101192","article-title":"The involvement of NLRP3 inflammasome in the treatment of Alzheimer's disease","volume":"64","author":"Feng","year":"2020","journal-title":"Ageing research reviews"},{"issue":"10","key":"10.1016\/j.biopha.2025.118164_bib225","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.tem.2020.03.004","article-title":"Mitochondria and T2D: Role of Autophagy, ER Stress, and Inflammasome","volume":"31","author":"Rocha","year":"2020","journal-title":"Trends in endocrinology and metabolism: TEM"},{"key":"10.1016\/j.biopha.2025.118164_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2024.174534","article-title":"S-glutathionylation in hepatocytes is involved in arsenic-induced liver fibrosis through activation of the NLRP3 inflammasome, an effect alleviated by NAC","volume":"947","author":"Li","year":"2024","journal-title":"The Science of the total environment"},{"key":"10.1016\/j.biopha.2025.118164_bib227","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.yjmcc.2013.11.015","article-title":"Fibroblasts in myocardial infarction: a role in inflammation and repair","volume":"70","author":"Shinde","year":"2014","journal-title":"Journal of molecular and cellular cardiology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib228","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0000000000000247","article-title":"Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse","volume":"66","author":"Marchetti","year":"2015","journal-title":"Journal of cardiovascular pharmacology"},{"issue":"42","key":"10.1016\/j.biopha.2025.118164_bib229","doi-asserted-by":"crossref","first-page":"8810","DOI":"10.2174\/0929867328666210705153109","article-title":"Targeting the NLRP3 Inflammasome in Diabetic Nephropathy","volume":"28","author":"Yang","year":"2021","journal-title":"Current medicinal chemistry"},{"key":"10.1016\/j.biopha.2025.118164_bib230","doi-asserted-by":"crossref","first-page":"1185317","DOI":"10.3389\/fimmu.2023.1185317","article-title":"Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols","volume":"14","author":"Jin","year":"2023","journal-title":"Frontiers in immunology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118164_bib231","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12967-023-04350-w","article-title":"Identification of pyroptosis-related genes and potential drugs in diabetic nephropathy","volume":"21","author":"Yan","year":"2023","journal-title":"Journal of translational medicine"},{"key":"10.1016\/j.biopha.2025.118164_bib232","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cca.2021.09.003","article-title":"Pyroptosis in diabetic nephropathy","volume":"523","author":"Al Mamun","year":"2021","journal-title":"Clinica chimica acta; international journal of clinical chemistry"},{"issue":"2","key":"10.1016\/j.biopha.2025.118164_bib233","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1042\/CS20210865","article-title":"Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease","volume":"136","author":"Ostergaard","year":"2022","journal-title":"Clinical science"},{"issue":"5","key":"10.1016\/j.biopha.2025.118164_bib234","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1007\/s10787-024-01556-2","article-title":"Review on the role of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome pathway in diabetes: mechanistic insights and therapeutic implications","volume":"32","author":"Satheesan","year":"2024","journal-title":"Inflammopharmacology"},{"issue":"12","key":"10.1016\/j.biopha.2025.118164_bib235","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012219","article-title":"Novel Insights Into the NLRP 3 Inflammasome in Atherosclerosis","volume":"8","author":"Jin","year":"2019","journal-title":"Journal of the American Heart Association"},{"issue":"2","key":"10.1016\/j.biopha.2025.118164_bib236","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/resp.12912","article-title":"Increased neutrophil expression of pattern recognition receptors during COPD exacerbations","volume":"22","author":"Pouwels","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.biopha.2025.118164_bib237","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.998574","article-title":"NLRP3-mediated pyroptosis in diabetic nephropathy","volume":"13","author":"Wan","year":"2022","journal-title":"Frontiers in pharmacology"},{"issue":"5","key":"10.1016\/j.biopha.2025.118164_bib238","doi-asserted-by":"crossref","DOI":"10.3390\/nu12051516","article-title":"Punicalagin Protects Diabetic Nephropathy by Inhibiting Pyroptosis Based on TXNIP\/NLRP3 Pathway","volume":"12","author":"An","year":"2020","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.biopha.2025.118164_bib239","doi-asserted-by":"crossref","DOI":"10.3390\/cells12121584","article-title":"The Interplay between Immune and Metabolic Pathways in Kidney Disease","volume":"12","author":"Qu","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.118164_bib240","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108053","article-title":"Targeting the NLRP3 inflammasome in cardiovascular diseases","volume":"236","author":"Toldo","year":"2022","journal-title":"Pharmacology & therapeutics"},{"key":"10.1016\/j.biopha.2025.118164_bib241","doi-asserted-by":"crossref","first-page":"1407721","DOI":"10.3389\/fcvm.2024.1407721","article-title":"Current research status and future prospects of NLRP3 inflammasome in cardiovascular diseases: a bibliometric and visualization analysis","volume":"11","author":"Miao","year":"2024","journal-title":"Frontiers in cardiovascular medicine"},{"key":"10.1016\/j.biopha.2025.118164_bib242","doi-asserted-by":"crossref","first-page":"1430236","DOI":"10.3389\/fphar.2024.1430236","article-title":"NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies","volume":"15","author":"Chen","year":"2024","journal-title":"Frontiers in pharmacology"},{"issue":"47","key":"10.1016\/j.biopha.2025.118164_bib243","article-title":"Desmosterol suppresses macrophage inflammasome activation and protects against vascular inflammation and atherosclerosis","volume":"118","author":"Zhang","year":"2021","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/j.biopha.2025.118164_bib244","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100554","article-title":"cholesterol) crystal clear path to inflammasome activation in atherosclerosis","volume":"65","author":"Li","year":"2024","journal-title":"Journal of lipid research"},{"key":"10.1016\/j.biopha.2025.118164_bib245","doi-asserted-by":"crossref","first-page":"1185233","DOI":"10.3389\/fimmu.2023.1185233","article-title":"Inflammasomes: a rising star on the horizon of COVID-19 pathophysiology","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:51:42Z","timestamp":1762311102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225003580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":242,"alternative-id":["S0753332225003580"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118164","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms and therapeutic potential of pharmacological agents targeting inflammasomes","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118164"}}